Cross-sectional study of the association of 5 single nucleotide polymorphisms with enalapril treatment response among South African adults with hypertension

dc.contributor.authorMasilela, Charity
dc.contributor.authorPearce, Brendon
dc.contributor.authorOngole, Joven J.
dc.contributor.authorAdeniyi, Oladele V.
dc.contributor.authorJohnson, Rabia
dc.contributor.authorBenjeddou, Mongi
dc.date.accessioned2022-03-10T08:12:30Z
dc.date.available2022-03-10T08:12:30Z
dc.date.issued2021-11-19
dc.description.abstractThis study investigates the association of 5 single nucleotide polymorphisms (SNPs) in selected genes (ABO, VEGFA, BDKRB2, NOS3, and ADRB2) with blood pressure (BP) response to enalapril. The study further assessed genetic interactions that exist within these genes and their implications in enalapril treatment response among South African adults with hypertension.A total of 284 participants belonging to the Nguni tribe of South Africa on continuous treatment for hypertension were recruited. Five SNPs in enalapril pharmacogenes were selected and genotyped using MassArray. Uncontrolled hypertension was defined as BP ≥140/90 mm Hg. The association between genotypes, alleles, and BP response to treatment was determined by fitting multivariate logistic regression model analysis, and genetic interactions between SNPs were assessed by multifactor dimensionality reduction.Majority of the study participants were female (75.00%), Xhosa (78.87%), and had uncontrolled hypertension (69.37%). All 5 SNPs were exclusively detected among Swati and Zulu participants. In the multivariate (adjusted) logistic model analysis, ADRB2 rs1042714 GC (adjusted odds ratio [AOR] = 2.31; 95% confidence interval [CI] 1.02-5.23; P = .044) and BDKRB2 rs1799722 CT (AOR = 2.74; 95% CI 1.19-6.28; P = .017) were independently associated with controlled hypertension in response to enalapril. While the C allele of VEGFA rs699947 (AOR = 0.37; 95% CI 0.15-0.94; P = .037) was significantly associated with uncontrolled hypertension. A significant interaction between rs699947, rs495828, and rs2070744 (cross-validation consistency = 10/10; P = .0005) in response to enalapril was observed.We confirmed the association of rs1042714 (ADRB2) and rs1799722 (BDKRB2) with controlled hypertension and established an interaction between rs699947 (VEGFA), rs495828 (ABO), and rs2070744 (NOS3) with BP response to enalapril. Our findings have provided substantial evidence for the use of SNPs as predictors for enalapril response among South Africans adults with hypertension. Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.en_US
dc.identifier.citationMasilela, Charity, et al. “Cross-Sectional Study of the Association of 5 Single Nucleotide Polymorphisms with Enalapril Treatment Response Among South African Adults with Hypertension.” Medicine (Baltimore), vol. 100, no. 46, 2021, pp. e27836–e27836, https://doi.org/10.1097/MD.0000000000027836.en_US
dc.identifier.issn15365964
dc.identifier.uri10.1097/MD.0000000000027836
dc.identifier.urihttp://hdl.handle.net/10566/7309
dc.language.isoenen_US
dc.publisherNLM (Medline)en_US
dc.relation.ispartofseriesMedicine;(2021) 100:46
dc.subjectAdolescenten_US
dc.subjectAdulten_US
dc.subjectAntihypertensive Agentsen_US
dc.subjectBlood Pressureen_US
dc.subjectBradykinin B2 Receptor Antagonistsen_US
dc.subjectCross-sectional studiesen_US
dc.subjectEnalaprilen_US
dc.subjectHypertensionen_US
dc.subjectNitric Oxide Synthaseen_US
dc.subjectPharmacogeneticsen_US
dc.subjectPolymorphismen_US
dc.subjectPolymorphismen_US
dc.subjectSingle Nucleotideen_US
dc.titleCross-sectional study of the association of 5 single nucleotide polymorphisms with enalapril treatment response among South African adults with hypertensionen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Masilela_et_al_2021_Cross-sectional_study.pdf
Size:
261.43 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: